INmune Bio to Attend RBC Healthcare Conference

Inmune Bio ( (INMB) ) just unveiled an update.

INmune Bio Inc. announced its participation in the 2025 RBC Capital Markets Global Healthcare Conference, scheduled for May 20-21, 2025, in New York. The company will engage in a fireside chat and virtual meetings, highlighting its focus on inflammation and immunology through its innovative product platforms. This participation underscores INmune Bio’s commitment to advancing its clinical-stage trials and enhancing its visibility in the biotechnology sector.

The most recent analyst rating on (INMB) stock is a Buy with a $22.00 price target. To see the full list of analyst forecasts on Inmune Bio stock, see the INMB Stock Forecast page.

Spark’s Take on INMB Stock

According to Spark, TipRanks’ AI Analyst, INMB is a Neutral.

Inmune Bio’s overall stock score is hindered by significant financial challenges, including declining revenue and ongoing losses. While technical analysis shows mixed signals, valuation metrics suggest overvaluation. Positive corporate events and earnings call highlights provide some optimism, but financial instability and operational challenges remain key risks.

To see Spark’s full report on INMB stock, click here.

More about Inmune Bio

INmune Bio Inc. is a clinical-stage biotechnology company that focuses on developing treatments targeting the innate immune system to combat diseases. The company operates three product platforms: the Dominant-Negative Tumor Necrosis Factor (DN-TNF) platform for conditions like Mild Alzheimer’s disease and treatment-resistant depression, the Natural Killer Cell Priming Platform for cancer treatment, and the CORDStrom™ platform for conditions such as recessive dystrophic epidermolysis bullosa.

Average Trading Volume: 257,507

Technical Sentiment Signal: Hold

Current Market Cap: $177.3M

For detailed information about INMB stock, go to TipRanks’ Stock Analysis page.